| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 377.18M | 352.21M | 374.84M | 300.81M | 254.88M | 137.00M |
| Gross Profit | 221.91M | 190.20M | 214.34M | 156.35M | 134.41M | 21.54M |
| EBITDA | 106.09M | 111.28M | 112.96M | 52.77M | 74.16M | -69.41M |
| Net Income | 39.55M | 26.06M | 25.34M | -22.80M | -22.33M | -143.78M |
Balance Sheet | ||||||
| Total Assets | 889.57M | 830.40M | 814.67M | 821.15M | 883.25M | 997.75M |
| Cash, Cash Equivalents and Short-Term Investments | 143.11M | 100.59M | 76.20M | 97.40M | 189.71M | 317.38M |
| Total Debt | 257.22M | 278.12M | 252.06M | 263.02M | 226.11M | 305.68M |
| Total Liabilities | 452.87M | 452.18M | 469.08M | 491.39M | 452.88M | 532.98M |
| Stockholders Equity | 349.53M | 299.47M | 273.14M | 263.36M | 356.08M | 385.49M |
Cash Flow | ||||||
| Free Cash Flow | 91.56M | 29.62M | 25.78M | -15.30M | -11.71M | -32.27M |
| Operating Cash Flow | 109.18M | 70.84M | 58.62M | 17.32M | 6.07M | -23.01M |
| Investing Cash Flow | -45.65M | -41.22M | -31.79M | -53.29M | -7.00K | -9.26M |
| Financing Cash Flow | -25.47M | -6.04M | -48.53M | -58.51M | -132.72M | 240.57M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $1.82B | 47.35 | 12.38% | ― | 9.30% | 67.19% | |
66 Neutral | $3.23B | -30.56 | -4.46% | ― | 24.54% | -119.75% | |
64 Neutral | $2.59B | 78.35 | ― | ― | 0.68% | -80.73% | |
60 Neutral | $48.67B | 4.58 | -11.27% | 4.14% | 2.83% | -41.78% | |
58 Neutral | $2.67B | 21.85 | 32.60% | 1.45% | 9.70% | -31.62% | |
52 Neutral | $2.61B | -12.98 | ― | ― | 97.19% | -21.46% | |
46 Neutral | $841.23M | -1.03 | ― | ― | 9.74% | 12.29% |
On November 3, 2025, IMAX Corporation announced the sale of $220 million in 0.750% Convertible Senior Notes due 2030, with an additional $30 million option exercised by initial purchasers, culminating in a total issuance of $250 million. The proceeds, approximately $241.1 million after expenses, will be used for capped call transactions and repurchasing 2026 notes, aiming to manage share dilution and optimize capital structure.
The most recent analyst rating on (IMAX) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on IMAX stock, see the IMAX Stock Forecast page.